Cancer Immunotherapy Platform
Different from any normal and pre-cancer cells, a cancer cell usually over-expresses one to many oncogenes and at the same time lost one to many
tumor suppressor genes depending on the stage of the tumor. Since oncogenes and tumor suppressor genes are usually cancer cell specific, many companies have
been developing monoclonal antibodies against cancer cells with some but limited success since cancer cells not only express these oncogenes
with multiple tumor suppressor gene deficiency, but also mutate quickly.
Another strategy is to teach or train part of the immune system such as T-cells, monocytes, macrophages, dendritic cells and natural killer
cells to recognize parts of cancer cells as foreign and kill them by delayed type hypersensitivity (DTH) or type IV hypersensitivity. Since
these immune responses are temporary, continual resupply of these trained lymphocytes is needed to fight cancer cells. However, cancer cells
continue to mutate and the trained lymphocytes will lose effectiveness against mutated cancer cells. Thus, continual supply of newly trained
lymphocytes are needed to combat against cancer.
BioMedicure's immunotherapy platform employs its proprietary CancerVaccine™ products to
transform the immune system against pre-cancer cells and cancer cells, including cancer stem cells specifically. BioMedicure is also developing
CancerVaccine™ induced cancer cell specific polyclonal antibodies,
AntiCancerBody™, kill cancer cells the natural most effective way.
Because the built-in genetic mutation information in CancerVaccine™ enables the immune system to produce immune responses
against pre-cancer and cancer cell specific antigens specifically and these immune responses are adaptive or acquired,
CancerVaccine™ vaccination can be used to prevent cancer and treat cancer as well. The vaccination
will meet unmet needs for pre-cancer patients, patients with tumors removed by biochemotherapy, surgery or radiotherapy, and
healthy individuals or high risk individuals who are concerned about certain types of cancer.
However, patients with metastasized cancer cells usually have suppressed immune systems and CancerVaccine™
vaccination may not work for them. In these cases, AntiCancerBody™ will be used to kill metastasized cancer cells specifically.
BioMedicure has been using syngeneic wild-type mouse tumor models to develop the cancer immunotherapy platform. The
safety and efficacy of CancerVaccine™ has been shown to be
advantageous over other known immunotherapies.BioMedicure has presented the data at the
AACR 101st Annual Meeting (Poster 4757: CancerVaccine: Novel proteinase treatment of
melanoma cancer cells produces a cancer vaccine with enhanced protective adaptive immune response).
According to the immunotherapy platform, BioMedicure has been able to develop over 20 CancerVaccine™
products to share with the cancer research community. These whole cell giant liposome cancer vaccine products are made out of corresponding in vitro "solid tumors"
grown from enriched cancer stem cells using a Tumorase™ Whole Cell Cancer Vaccine Kit (TK-110 view).
|